Dori Thomas-Karyat
Chief Executive Officer & founder Synthis Therapeutics, Inc
Dr. Dori Thomas-Karyat is the Founder and CEO of Synthis Therapeutics, where she leads the development of a first-in-class ADC platform targeting TGF-ß-driven diseases, including fibrotic disorders such as IPF. A recognized expert in TGF-ß biology with over 20 years of experience in oncology, fibrosis, and immuno-oncology, she has held leadership roles in drug discovery at AbbVie and Roche. Dr. Thomas-Karyat completed her postdoctoral fellowship at Memorial Sloan Kettering Cancer Center in the lab of TGF-ß pioneer Dr. Joan Massagué and holds a Ph.D. in Immunology from Washington University School of Medicine in St. Louis. She has been awarded multiple SBIR grants, holds six issued patents, and is a frequent speaker at scientific conferences.
Seminars
- Assessing past and present targets, what has the field learned from antifibrotic failures, and is there still potential in pathways like TGF-β?
- Exploring emerging therapeutic strategies from repair and regeneration to RNA-based therapies, cell and gene therapy, and immunomodulation
- Identifying unmet opportunities by exploring what mechanisms remain underexplored, where should research efforts be focused next to drive meaningful progress?
- Exploring the potential of ADCs to selectively deliver therapeutics while minimizing systemic toxicity
- Revaluating specific targeting of TGF-β in fibrosis by leveraging non-cytotoxic payloads to modulate TGF-β signaling without adverse effects
- Integrating ADCs with emerging approaches to enhance efficacy and safety in IPF treatment
